Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice
We investigated the effects of tivozanib, an oral vascular endothelial growth factor (VEGF)
receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization (CNV) in
mice. C57BL/6 mice were treated with tivozanib (1 mg/kg/day) or vehicle at the onset (day 0)
of the study and experimental CNV was induced by laser photocoagulation the following
day. In the other groups, tivozanib or vehicle was started 7 days after the laser
photocoagulation to determine the effects of the drug on established CNV. To evaluate …
receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization (CNV) in
mice. C57BL/6 mice were treated with tivozanib (1 mg/kg/day) or vehicle at the onset (day 0)
of the study and experimental CNV was induced by laser photocoagulation the following
day. In the other groups, tivozanib or vehicle was started 7 days after the laser
photocoagulation to determine the effects of the drug on established CNV. To evaluate …